Rui Qiao

DIAVariant identifies low abundance peptide variants from DIA-MS data without relying on reference databases, improving variant discovery while maintaining specificity.

NovoBoard evaluates de novo peptide sequencing methods using benchmark datasets and FDR estimation to assess accuracy and significance of peptide-spectrum matches.

This study introduces DeepNovo Peptidome and DeepSelf for neoantigen discovery and validation using immunopeptidomics and deep learning, demonstrating their application in cervical cancer tissues.

The paper introduces a personalized deep learning workflow to identify neoantigens from mass spectrometry data, improving accuracy and discovery rates in melanoma patients.